GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Todos Medical Ltd (OTCPK:TOMDF) » Definitions » ROCE %

Todos Medical (Todos Medical) ROCE % : -1,222.77% (As of Sep. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Todos Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Todos Medical's annualized ROCE % for the quarter that ended in Sep. 2022 was -1,222.77%.


Todos Medical ROCE % Historical Data

The historical data trend for Todos Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Todos Medical ROCE % Chart

Todos Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROCE %
Get a 7-Day Free Trial -262.35 - - - -718.29

Todos Medical Quarterly Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -168.26 -585.88 -94.23 -703.53 -1,222.77

Todos Medical ROCE % Calculation

Todos Medical's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-14.707/( ( (6.009 - 8.069) + (15.115 - 8.96) )/ 2 )
=-14.707/( (-2.06+6.155)/ 2 )
=-14.707/2.0475
=-718.29 %

Todos Medical's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=-9.452/( ( (13.85 - 12.32) + (14.227 - 14.211) )/ 2 )
=-9.452/( ( 1.53 + 0.016 )/ 2 )
=-9.452/0.773
=-1,222.77 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Todos Medical  (OTCPK:TOMDF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Todos Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Todos Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Todos Medical (Todos Medical) Business Description

Traded in Other Exchanges
N/A
Address
121 Derech Menachem Begin, 30th Floor, Tel Aviv, ISR, 6701203
Todos Medical Ltd is an in vitro diagnostics company. Its operating segments are Breast Cancer Test, Alzheimer's, and COVID-19 testing. The company generates all of its revenue from the United States.
Executives
Gerald Commissiong director, officer: CEO and Director 675 ALMANOR AVENUE, SUNNYVALE CA 94085
Strategic Investment Holdings, Llc 10 percent owner 875 CARRETERA 693, SUITE 201, DORADO PR 00646